Upstream stimulatory factors regulate the C/EBP alpha gene during differentiation of 3T3-L1 preadipocytes.
Kim JW., Monila H., Pandey A., Lane MD.
Animal Study, published in Biochem Biophys Res Commun (2007) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Biochem Biophys Res Commun (2007)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 17239350
- DOI
- 10.1016/j.bbrc.2007.01.008
Abstract (original English)
During adipocyte differentiation, CCAAT/enhancer-binding protein alpha (C/EBPalpha) functions as a pleiotropic transcriptional activator of numerous adipocyte genes. The promoter of the C/EBPalpha gene has an E-box upstream of C/EBP binding site. Deletion or mutation of the E-box decreases promoter activity, suggesting that the E-box participates in the regulation of C/EBPalpha expression. Protein binding to the E-box during the adipocyte differentiation is increased as indicated by EMSA and UV cross-linking. Purification of the E-box binding proteins from differentiated 3T3-L1 adipocytes, showed that USF and AP-4 are associated with the E-box. Supershift analysis showed that USF1 and USF2 bind to this element as heterodimers, whereas the addition of anti-AP-4 antibody enhanced the binding complex, suggesting that AP-4 negatively regulates the promoter activity. The expression of AP-4 is reciprocally regulated with USF-1 during adipocyte differentiation. These findings suggest that USF-1 and 2 play roles in C/EBPalpha expression, whereas the AP-4 represses it.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.